4//SEC Filing
SCHIFF ANDREW N 4
Accession 0001209191-23-034411
CIK 0001557746other
Filed
Jun 4, 8:00 PM ET
Accepted
Jun 5, 4:53 PM ET
Size
13.7 KB
Accession
0001209191-23-034411
Insider Transaction Report
Form 4
SCHIFF ANDREW N
Director
Transactions
- Exercise/Conversion
Common Stock
2023-06-02+4,507→ 4,507 total - Award
Restricted Stock Units
2023-06-01+4,660→ 4,660 total→ Common Stock (4,660 underlying) - Award
Stock Option (Right to Buy)
2023-06-01+15,750→ 15,750 totalExercise: $8.70Exp: 2033-05-31→ Common Stock (15,750 underlying) - Exercise/Conversion
Restricted Stock Units
2023-06-02−4,507→ 0 total→ Common Stock (4,507 underlying)
Holdings
- 434,455(indirect: By Aisling Capital IV LP)
Common Stock
Footnotes (6)
- [F1]Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
- [F2]The reportable securities are owned directly by Aisling Capital IV, LP ("Aisling"), and held indirectly by Aisling Capital Partners IV, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners IV LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members of Aisling Partners. The individual managing members (collectively, the "Managers") of Aisling Partners are Dr. Andrew Schiff and Steve Elms. Aisling GP, Aisling Partners, and the Managers share voting and dispositive power over the shares directly held by Aisling. Dr. Schiff disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.
- [F3]This grant was made pursuant to the issuer's ninth amended and restated non-employee director compensation policy.
- [F4]The shares subject to this option will vest in twelve equal monthly installments commencing July 1, 2023, subject to Reporting Person's continuous service through each such date.
- [F5]The shares underlying these restricted stock units will vest on June 1, 2024, subject to the Reporting Person's continuous service through such date.
- [F6]The shares underlying these restricted stock units vested on June 2, 2023.
Documents
Issuer
Aclaris Therapeutics, Inc.
CIK 0001557746
Entity typeother
Related Parties
1- filerCIK 0001172252
Filing Metadata
- Form type
- 4
- Filed
- Jun 4, 8:00 PM ET
- Accepted
- Jun 5, 4:53 PM ET
- Size
- 13.7 KB